Mikhail V. Blagosklonny graduated with an MD and PhD from First Pavlov State Medical
University of St. Petersburg, Russia. Dr. Mikhail V. Blagosklonny has then
Immigrated to America, where he received the prestigious Fogarty Fellowship from the National Institutes of Health.
During his fellowship in Leonard Neckers’ lab at the National
Cancer Institute (NCI), he was a co-author of 18 publications on
Diversified biomedical topics, like targeting
HSP90, p53, Bcl2, Erb2, and Raf-1. He also was the last writer on a clinical phase I/II
Trial publication.
 
After authoring seven papers during a brief yet resulting
Senior research fellowship in the El-Deiry Cancer Research Lab at the University of Pennsylvania,
Dr. Blagosklonny returned to NCI to team up with Tito Fojo. Together, they
Published 26 papers. In addition, Dr. Misha Blagosklonny published many of experimental research papers and theoretical papers as sole
Writer. The abovementioned sole-author publications
Encompassed two important themes.
The first of those focused on selectively killing cancer
Cells with deregulated cell cycle or drug resistance by
Verifying their resistance. The results and underlying
Concept were so revolutionary that they were improperly cited by
Other scientists as “reversal of resistance, ” even though the work was
Named, “Exploiting of drug resistance instead of its reversal. ” One big
Supporter of this concept was the world-famous scientist Arthur Pardee, with whom Dr.
Blagosklonny co-authored a joint article in 2001.
 
The second theme throughout Dr. Blagosklonny’s sole-author articles
Is a research method to produce knowledge by
Bringing several facts together from seemingly irrelevant fields.
This results in new notions with testable forecasts, which in
Turn can be “tested” via analyzing the literature further. Once again, the
Notion was co-authored by Arthur Pardee in a 2002 publication in Nature. The
First success of the new research methodology was the description of the feedback
Regulation of p53, as supported by the discovery of mdm2/p53 loop; and the
Explanation why mutant p53 is always overexpressed, published in 1997. The most
Significant outcome revealed by Dr.
Blagosklonny’s research methods is the hyperfunction (or quasi-programmed)
Theory of aging and the revelation of rapamycin as an exceptionally well-tolerated
Anti-aging medicine, published in 2006. As mentioned in Scientific American,
Michael Hall, who discovered mTOR in 1991, gives Dr. Blagosklonny recognition for
“connecting dots that others can’t even see. ”
 
In 2002, Dr. Blagosklonny became associate professor of medicine at New York Medical College.
He decided to assume responsibilities as a senior scientist at Ordway
Research Institute in Albany, New York, in 2005, before accepting another
Position at Roswell Park Cancer Institute as professor of oncology in 2009.
 
Since coming to Roswell Park Comprehensive Cancer Center in 2009, Dr. Blagosklonny
Has studied the prevention of cancer (an age-related disease) via
Stopping organism aging — in other words, “preventing cancer
Via staying young. ” His lab closely collaborated with
Andrei Gudkov’s and conducted research on the suppression of
Cellular senescence, namely suppression of cellular conversion from healthy quiescence to
Permanent senescence. This led to the discovery of extra anti-aging
Medicines beyond rapamycin. The cell culture studies were
Accompanied by studies in mice, including a few models such as
Normal and aging mice, p53-deficient mice, and mice on a high-fat diet.
 
Dr. Misha Blagosklonny has also published extensively on the stoppage of cellular
Senescence by rapamycin as well as other mTOR inhibitors, life
Prolongation and cancer stoppage in mice, and combinations of anti-
Aging medications to be appliedamong humans. A
Rapamycin-based combination of seven clinically available drugs has
Been named the “Koschei Formula” and is now utilized for the treatment of aging in patients
At the Alan Green Clinic in Little Neck, New York.